A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab

DOI Web Site Web Site 被引用文献1件
  • Irene M Vavasour
    Department of Radiology and UBC MRI Research Centre, The University of British Columbia, Vancouver, BC, Canada
  • Roger Tam
    Department of Radiology, The University of British Columbia, Vancouver, BC, Canada/School of Biomedical Engineering, The University of British Columbia, Vancouver, BC, Canada
  • David KB Li
    Department of Radiology, The University of British Columbia, Vancouver, BC, Canada/Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada
  • Cornelia Laule
    Department of Radiology, The University of British Columbia, Vancouver, BC, Canada/Department of Pathology & Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada/Department of Physics & Astronomy, The University of British Columbia, Vancouver, BC, Canada/International Collaboration on Repair Discoveries, The University of British Columbia, Vancouver, BC, Canada
  • Carolyn Taylor
    Department of Statistics, The University of British Columbia, Vancouver, BC, Canada
  • Shannon H Kolind
    Department of Radiology, The University of British Columbia, Vancouver, BC, Canada/Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada/Department of Physics & Astronomy, The University of British Columbia, Vancouver, BC, Canada/International Collaboration on Repair Discoveries, The University of British Columbia, Vancouver, BC, Canada
  • Alex L MacKay
    Department of Radiology, The University of British Columbia, Vancouver, BC, Canada/Department of Physics & Astronomy, The University of British Columbia, Vancouver, BC, Canada
  • Adil Javed
    Department of Neurology, The University of Chicago, Chicago, IL, USA
  • Anthony Traboulsee
    Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada

説明

<jats:sec><jats:title>Background:</jats:title><jats:p> Tissue damage in both multiple sclerosis (MS) lesions and normal-appearing white matter (NAWM) are important contributors to disability and progression. Specific aspects of MS pathology can be measured using advanced imaging. Alemtuzumab is a humanised monoclonal antibody targeting CD52 developed for MS treatment. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate changes over 2 years of advanced magnetic resonance (MR) metrics in lesions and NAWM of MS patients treated with alemtuzumab. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> A total of 42 relapsing–remitting alemtuzumab-treated MS subjects were scanned for 2 years at 3 T. T<jats:sub>1</jats:sub> relaxation, T<jats:sub>2</jats:sub> relaxation, diffusion tensor, MR spectroscopy and volumetric sequences were performed. Mean T<jats:sub>1</jats:sub> and myelin water fraction (MWF) were determined for stable lesions, new lesions and NAWM. Fractional anisotropy was calculated for the corpus callosum (CC) and N-acetylaspartate (NAA) concentration was determined from a large NAWM voxel. Brain parenchymal fraction (BPF), cortical thickness and CC area were also calculated. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> No change in any MR measurement was found in lesions or NAWM over 24 months. BPF, cortical thickness and CC area all showed decreases in the first year followed by stability in the second year. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants. </jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

問題の指摘

ページトップへ